ESMO Events 2025

Meetings 打開新的分頁／視窗 | ESMO 打開新的分頁／視窗

Welcome to our ESMO Virtual Congress site where we showcase the very best from ESMO's flagship portfolio.

ESMO European Lung Cancer Congress 2025 打開新的分頁／視窗

The European Lung Cancer Congress is a collaborative effort of the most important multidisciplinary societies representing thoracic oncology specialists, working together to advance science, disseminate education and improve the practice of lung cancer specialists worldwide.

Medical oncologists, radiation oncologists, thoracic surgeons, respiratory physicians / pneumologists, interventional radiologists and pathologists all benefit from its comprehensive and stimulating programme.

Below a collection of papers recently published in ESMO’s premier journals carefully selected to reflect the themes of the meeting.

Annals of Oncology

• Results from a phase Ib study of telisotuzumab vedotin in combination with osimertinib in patients with c-Met protein-overexpressing, EGFR-mutated locally advanced/metastatic non-small-cell lung cancer (NSCLC) after progression on prior osimertinib 打開新的分頁／視窗 H. Horinouchi, B.C. Cho, D.R. Camidge, K. Goto, P. Tomasini, Y. Li, A. Vasilopoulos, P. Brunsdon, D. Hoffman, W. Shi, E. Bolotin, V. Blot, J. Goldman

• Lung adenocarcinomas with mucinous histology: clinical, genomic, and immune microenvironment characterization and outcomes to immunotherapy-based treatments and KRASG12C inhibitors 打開新的分頁／視窗 A. Di Federico, L. Hong, A. Elkrief, R. Thummalapalli, A.J. Cooper, B. Ricciuti, S. Digumarthy, J.V. Alessi, P. Gogia, F. Pecci, M. Makarem, M.M. Gandhi, E. Garbo, A. Saini, A. De Giglio, V. Favorito, S. Scalera, L. Cipriani, D. Marinelli, D. Haradon, T. Nguyen, J. Haradon, E. Voligny, V. Vaz, F. Gelsomino, F. Sperandi, B. Melotti, M. Ladanyi, J. Zhang, D.L. Gibbons, J.V. Heymach, M. Nishino, J. Lindsay, S.J. Rodig, K. Pfaff, L.M. Sholl, X. Wang, B.E. Johnson, P.A. Jänne, N. Rekhtman, M. Maugeri-Saccà, R.S. Heist, A. Ardizzoni, M.M. Awad, K.C. Arbour, A.J. Schoenfeld, N.I. Vokes, J. Luo

ESMO Open

• The impact of co-occurring tumor suppressor mutations with mEGFR as early indicators of relapse in lung cancer 打開新的分頁／視窗 S. Hait, V. Noronha, A. Chowdhury, A. Chaudhary, B. Bawaskar, G. Dahimbekar, S. Ahmad, A. Joshi, V. Patil, N. Menon, M. Shah, R. Kaushal, A. Choughule, A. Bharde, J. Khandare, G. Shafi, D. Lakhwani, S. Desai, P. Chandrani, K. Prabhash, A. Dutt

• Comparative profiling of surgically resected primary tumors and their lymph node metastases in small-cell lung cancer 打開新的分頁／視窗 K. Csende, B. Ferencz, K. Boettiger, M.D. Pozonec, A. Lantos, A. Ferenczy, O. Pipek, A. Solta, B. Ernhofer, V. Laszlo, E. Megyesfalvi, K. Schelch, V. Pozonec, J. Skarda, V. Skopelidou, Z. Lohinai, C. Lang, L. Horvath, K. Dezso, J. Fillinger, F. Renyi-Vamos, C. Aigner, B. Dome, Z. Megyesfalvi

Immuno-Oncology and Technology

• Potentiating intratumoral therapy with immune checkpoint inhibitors: shifting the paradigm of multimodality therapeutics 打開新的分頁／視窗 B.E. Nelson, A. Naing, S. Fu, R.A. Sheth, R. Murthy, S. Piha-Paul

ESMO Real World Data and Digital Oncology

• Observational study on the safety and effectiveness of SARS-CoV-2 vaccination in patients with lung cancer 打開新的分頁／視窗 E. Nadal, T. Morán, A. Estival, M.Á. Sala, M. Antoñanzas, J.G. González, M.P. Diz-Taín, M. Martínez, E. Azcona, J. Baena, B. Campos, J.D. Cumplido, S. Cerezo, A. Díaz-Serrano, M. Guirado, X. Mielgo, M. Saigí, Z. Vidales on behalf of the Spanish Lung Cancer Group

• Definitions, measurement, and reporting of progression-free survival in randomized clinical trials and observational studies of patients with advanced non-small-cell lung cancer treated with immunotherapy: a scoping review 打開新的分頁／視窗 M.V. Verschueren, V.P. Tassopoulou, R. Visscher, J. Schuurkamp, B.J.M. Peters, M. Koopman, E.M.W. van de Garde, A.C.G. Egberts, L.T. Bloem

ESMO affiliated journals

• Selecting systemic treatment for metastatic neuroendocrine tumors of the lung—current evidence and clinical implications 打開新的分頁／視窗 Philipp Melhorn, Markus Raderer, Barbara Kiesewetter

• Antibody-drug conjugates in NSCLC with actionable genomic alterations: Optimizing smart delivery of chemotherapy to the target 打開新的分頁／視窗 Giannis Mountzios, Stephanie P.L. Saw, Lizza Hendriks, Jessica Menis, Tina Cascone, Oscar Arrieta, Jarushka Naidoo, Prodromos Koutoukoglou, Massimiliano Cani, Antoine Lefevre, Alfredo Addeo, Solange Peters, Jordi Remoni

• Proposal of real-world solutions for the implementation of predictive biomarker testing in patients with operable non-small cell lung cancer 打開新的分頁／視窗 Paul Hofman, Petros Christopoulos, Nicky D’Haene, John Gosney, Nicola Normanno, Ed Schuuring, Ming-Sound Tsao, Christine Quinn, Jayne Russell, Katherine E Keating, Fernando López-Ríos

• Identification of key gene signatures for predicting chemo-immunotherapy efficacy in extensive-stage small-cell lung cancer using machine learning 打開新的分頁／視窗 Daichi Fujimoto, Ryota Shibaki, Keiichi Kimura, Koji Haratani, Motohiro Tamiya, Takashi Kijima, Yuki Sato, Akito Hata, Toshihide Yokoyama, Yoshihiko Taniguchi, Junji Uchida, Hisashi Tanaka, Naoki Furuya, Satoru Miura, Mihoko Imaji Onishi, Shinya Sakata, Eisaku Miyauchi, Nobuyuki Yamamoto, Yasuhiro Koh, Hiroaki Akamatsu

ESMO's Journal Portfolio

While diverse in nature and in content, these journals offer ESMO members and the oncology community a highly visible platform to publish important scientific studies, and a highly credible source for educational updates. Elsevier is the proud publisher of Annals of Oncology, Immuno-Oncology and Technology (IOTECH), ESMO Open, ESMO Gastrointestinal Oncology, ESMO Real World Data and Digital Oncology, ESMO Rare Cancers, and ESMO Affiliated Journals The Breast, Lung Cancer, Cancer Treatment Reviews and Clinical Lymphoma Myeloma and Leukemia.